Core Insights - Bioventus Inc. reported a 15.0% increase in Q3 revenue, marking the fourth consecutive quarter of double-digit organic growth, driven by strong performance in Pain Treatments and Surgical Solutions [2][5] - The company achieved a gross margin expansion of 200 basis points and generated cash from operations of $10.3 million, an increase of $18.6 million compared to the previous year [1][3] - The net loss from continuing operations decreased to $5.4 million from $8.8 million in the prior-year period, with adjusted EBITDA rising 8.4% to $23.6 million [3][4] Financial Performance - Q3 2024 worldwide revenue reached $139.0 million, up from $120.8 million in Q3 2023, with notable growth in Pain Treatments (16.3%) and Surgical Solutions (18.6%) [2][5] - Adjusted EBITDA for the third quarter was $23.6 million, reflecting strong revenue growth compared to $21.7 million in the prior year [3][35] - The company reported a loss per share of $0.07, an improvement from a loss of $0.12 in the prior-year period [4][18] Revenue Breakdown - U.S. net sales totaled $122.9 million, a 15.7% increase year-over-year, with Pain Treatments contributing $56.3 million and Surgical Solutions $41.2 million [5][6] - International net sales amounted to $16.1 million, a 10.2% increase, with Pain Treatments growing by 29.3% [5][6] Strategic Developments - Bioventus is focused on executing strategic priorities to enhance revenue growth and profitability while reducing leverage to increase shareholder value [2][7] - The company has reached an agreement to divest its Advanced Rehabilitation Business for up to $45.0 million, expected to close by early 2025, which will help reduce debt and concentrate on core businesses [7][8] Future Guidance - For the twelve months ending December 31, 2024, Bioventus expects net sales between $562 million and $567 million, with adjusted EBITDA projected at $104 million to $107 million [8]

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Bioventus (BVS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Bioventus is one of 1024 companies in the Medical group. The Medical group currently sits ...

Core Viewpoint - Bioventus (BVS) is set to report its third-quarter 2024 earnings, with sales and earnings estimates at $132.6 million and 6 cents per share, respectively. The company has shown strong earnings surprises in recent quarters, indicating positive momentum in its financial performance [1][3]. Financial Performance - The earnings estimates for Bioventus' 2024 and 2025 EPS have remained stable at 40 cents and 45 cents, respectively, over the past 60 days [1]. - Bioventus has delivered an earnings surprise of 171.43% in the last reported quarter, with an average surprise of 102.86% over the trailing four quarters [3][4]. Revenue Growth - The company is experiencing double-digit revenue growth in its Pain Treatments and Surgical Solutions segments, with organic sales rising nearly 14% year over year in Q2 2024 [8]. - Bioventus has raised its financial guidance for 2024, expecting net sales between $557 million and $567 million, significantly higher than the original guidance of $520-$535 million [16]. Profitability and Divestitures - Management is focusing on improving profitability by divesting lower-margin businesses, including the sale of its Wound business for $85 million and the Advanced Rehabilitation business for $45 million [9][10]. - These divestitures are expected to enhance margins and cash flow, with adjusted EBITDA increasing by 22% year over year and adjusted gross margin expanding by 180 basis points to 75.8% [10]. Liquidity and Debt Management - The proceeds from divestitures are improving Bioventus' liquidity position, with a net leverage ratio reduced to less than four, and plans to lower it to below three times by the end of 2025 [11]. - Investors are likely to seek updates on the company's progress regarding liquidity and financial efficiency targets [11]. Stock Performance and Valuation - Year-to-date, Bioventus stock has surged 147.8%, outperforming the industry and the S&P 500, which saw a decline of 5.9% [13]. - The stock is currently trading at a price/sales ratio of 1.56, lower than the industry average of 2.06, indicating it is trading at a discount [15]. Investment Thesis - The company's strategic focus on accelerating growth, enhancing profitability, and improving liquidity is yielding positive results, making Bioventus a compelling addition to investment portfolios [16].

DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November 5, 2024. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0 ...

Core Viewpoint - Bioventus (BVS) has experienced a significant stock price increase of 73% over the past three months, outperforming the industry and the S&P 500, driven by strong sales performance and improved financial guidance for 2024 [1][2][4]. Group 1: Stock Performance - BVS shares have surged 73% in the last three months, compared to the industry's growth of 1.3% [1]. - The stock is trading above both the 50-day and 200-day moving averages, indicating strong momentum [1]. Group 2: Sales and Revenue Growth - The increase in stock price is attributed to encouraging sales performance, particularly in the Pain Treatments and Surgical Solutions segments [2]. - Organic sales grew nearly 14% year over year in Q2 2024, continuing a trend of double-digit growth [3]. - Management has raised the 2024 revenue guidance twice this year, now expecting net sales between $557 million and $567 million, up from the original guidance of $520-$535 million [4]. Group 3: Financial Efficiency and Divestitures - Bioventus is focusing on improving financial efficiency and liquidity by divesting lower-margin businesses, including the sale of its Wound business for $85 million and the Advanced Rehabilitation business for $45 million [5]. - These divestitures are expected to enhance margins and increase cash flow, which can be reinvested into the core business or used to reduce leverage [5]. - Adjusted EBITDA increased by 22% year over year, with adjusted gross margin expanding by 180 basis points to 75.8% [5]. Group 4: Debt Reduction - The company has made significant progress in reducing its debt, bringing it below four times and aiming for less than three times by the end of next year [6]. Group 5: Valuation and Earnings Estimates - BVS is currently trading at a price/sales ratio of 1.52, which is lower than the industry average of 2.17, indicating a potential undervaluation [7]. - Earnings per share estimates for 2024 and 2025 remain consistent at 40 and 45 cents, respectively [8]. Group 6: Investment Recommendation - Given the strong commercial execution and focus on growth, profitability, and liquidity, Bioventus is recommended for addition to investment portfolios, especially as it trades at a discount to the industry [9].

Group 1: Stock Performance - The stock price of Bioventus (BVS) has more than doubled in the past six months, significantly outperforming the industry's 5.1% rise [1] - BVS shares are trading above the 50-day and 200-day moving averages, indicating strong market performance [1] Group 2: Business Segments and Revenue Growth - Bioventus operates in three segments: Pain Treatments, Restorative Therapies, and Surgical Solutions [3] - The company is experiencing double-digit revenue growth in both the Pain Treatments and Surgical Solutions segments, with organic sales rising nearly 14% year over year in Q2 2024 [4] Group 3: Profitability and Liquidity Improvements - Bioventus is improving profitability by focusing on higher-margin core businesses, having sold its Wound business for $85 million and planning to divest its Advanced Rehabilitation business [5] - Adjusted EBITDA increased by 22% year over year in Q2 2024, and adjusted gross margin expanded by 180 basis points to 75.8% [5] Group 4: Financial Guidance and Estimates - Management raised its financial guidance for 2024 for the second time this year, with net sales expected to be between $557 million and $567 million, up from the previous guidance of $535-$550 million [7] - Earnings per share estimates for 2024 have risen from 27 cents to 40 cents in the past 60 days, reflecting analysts' optimistic outlook [9][10] Group 5: Market Position and Investment Recommendation - Bioventus is trading at a discount to the industry, with a price/sales ratio of 1.40 compared to the industry average of 2.20 [9] - The company's focus on accelerating growth, boosting profitability, and improving liquidity is enhancing its presence in the medical products market, making it a strong candidate for investment [12][13]

Core Viewpoint - Bioventus (BVS) is a strong buy with a focus on developing drugs for quick and safe healing, particularly targeting osteoarthritis and bone healing [1] Company Overview - Bioventus, Inc. is a medical technology company specializing in proprietary orthobiologic products for musculoskeletal conditions, founded on November 23, 2011, and headquartered in Durham, NC [2] Earnings History - Bioventus has a solid earnings history, consistently beating the Zacks Consensus in the last three quarters, with an average positive earnings surprise of 102% over the last four quarters [4] Earnings Estimates Revisions - Annual earnings estimates for Bioventus are increasing, with the full year 2024 estimate rising from $0.27 to $0.40, and next year's estimate moving up from $0.43 to $0.45 over the last 30 days [5] Growth Projections - For 2024, Bioventus is expected to achieve 9.45% growth with projected sales of $560 million, increasing to $593 million in the following year for a 5.8% growth [6] Valuation Metrics - The forward PE ratio is 24x, which is considered high for the expected topline growth, while the price to book ratio is 4.1x and price to sales ratio is 1.46x, indicating potential for revenue expansion [7] - Operating margins have improved from 1% to 5.1% and up to 5.7% over the last three quarters, suggesting that growing sales and higher margins will lead to increased earnings per share [7]

Bioventus Inc. (NASDAQ:BVS) Q2 2024 Earnings Conference Call August 7, 2024 8:03 AM ET Corporate Participants Dave Crawford - VP, IR & Treasurer Robert Claypoole - President and Chief Executive Officer Mark Singleton - Senior Vice President and Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Operator Good day, and welcome to the Bioventus Second Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions]. Please note ...

DURHAM, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer, will participate in a fireside chat at the Canaccord Genuity Global Growth Conference on Wednesday, August 14, 2024, at 9:00 a.m. ET. A live webcast of the presentation, followed by a question-and-answer session will be available on the "Investors" section of the Company's website at www.bioven ...

DURHAM, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer, will participate in a fireside chat at the Canaccord Genuity Global Growth Conference on Wednesday, August 14, 2024, at 9:00 a.m. ET. A live webcast of the presentation, followed by a question-and-answer session will be available on the "Investors" section of the Company's website at www.bioven ...